Buchanan is a national law firm with a strong reputation for providing progressive, industry-leading legal, business, regulatory and government relations advice to our regional, national and international clients. Our 450 attorneys and government relations professionals across 17 offices proudly represent some of the highest profile and innovative companies in the nation, including 50 of the Fortune 100. While we service a wide range of clients, Buchanan has especially deep experience in the energy, finance, healthcare and life sciences industries. We bring to our clients an intimate knowledge of the players, market forces and political and regulatory landscape and use our full-service offerings to protect, defend and advance our clients’ businesses.
Michael assists biotech and pharmaceutical companies with patent litigation, portfolio management, patent prosecution and patent licenses. He also helps clients with all aspects of patent monetization or acquisition, including due diligence, strategy development, negotiation, drafting and execution of agreements.
His clients are innovator companies whose products include technologies related to antibodies, vaccines, pharmaceuticals, chemicals, nutrition and medical devices. He is experienced in litigation under the Hatch-Waxman Act (ANDA) as well as the Biologics Price Competition and Innovation Act (BPCIA).
Michael has extensive experience in inter partes proceedings before the Trademark Trial and Appeal Board and has represented clients in U.S. district courts, before the International Trade Commission and in appeals before the United States Court of Appeals for the Federal Circuit.